Lexicon Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Lexicon Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $3.72. The average 1-year stock price forecast is 97.87% higher than the current stock price, while the lowest is $1.50 (-20.21%) and the highest is $6.00 (+219.15%).

Price Target: $3.72 (+97.87%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.50	$3.72	$3.10	$6.00
Change	-20.21%	+97.87%	+64.89%	+219.15%

* Price targets were last updated on May 11, 2026.

Analyst Ratings

The average analyst rating for Lexicon Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	2	2	2
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yigal Nochomovitz Citi	Citi	Buy Maintains $2.3 → $3.1	Buy	Maintains	$2.3 → $3.1	+64.89%	May 11, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Maintains $6	Buy	Maintains	$6	+219.15%	May 8, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $6	Buy	Maintains	$6	+219.15%	Apr 15, 2026
Unknown Analyst Leerink Partners No rating	Leerink Partners	Hold Reiterates $1	Hold	Reiterates	$1	-46.81%	Mar 6, 2026

Financial Forecast

Revenue This Year

38.17M

from 49.80M

-23.37%

from 49.80M

Revenue Next Year

20.15M

from 38.17M

-47.20%

from 38.17M

EPS This Year

-0.16

from -0.14

EPS Next Year

-0.21

from -0.16

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	298.00K	139.00K	1.20M	31.08M	49.80M	38.17M
Revenue Growth	-98.76%	-53.36%	766.19%	2,481.48%	60.24%	-23.37%
Gross Profit	-54.75M	-52.38M	-4.02M	24.63M	43.24M	37.78M
Gross Margin	-18,371.81%	-37,681.29%	-333.89%	79.23%	86.82%	99.00%
Operating Income	-87.09M	-100.46M	-171.75M	-196.02M	-48.91M	-68.43M
Net Income	-87.76M	-101.94M	-177.12M	-200.40M	-50.34M	-66.94M
EPS	-	-	-	-	-0.14	-0.16
Free Cash Flow	-55.54M	-52.65M	-94.97M	-105.30M	-47.82M	583.00M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	44.8M
Avg	38.2M
Low	31.1M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-10.0%
Avg	-23.4%
Low	-37.5%

EPS Forecast

EPS	2026	2027	2028
High	-0.14
Avg	-0.16
Low	-0.18

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-